Protection of the kidney by thiazolidinediones: an assessment from bench to bedside (Q36554451)

14 August 2017

1 reference

title

Protection of the kidney by thiazolidinediones: an assessment from bench to bedside (English)

1 reference

14 August 2017

Sarafidis PA

1

1 reference

PubMed ID

16883325

14 August 2017

Bakris GL

series ordinal

2

1 reference

PubMed ID

16883325

14 August 2017

language of work or name

English

0 references

publication date

2 August 2006

1 reference

14 August 2017

1 reference

14 August 2017

70

1 reference

14 August 2017

7

1 reference

14 August 2017

1223-1233

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.ki.5001620

14 August 2017

0 references

cites work

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Is proteinuria a plausible target of therapy?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Microalbuminuria and markers of the atherosclerotic process: the D.E.S.I.R. study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Association between serum C-reactive protein levels and microalbuminuria: a population-based cross-sectional study in northern Iwate, Japan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

General characteristics of the insulin resistance syndrome: prevalence and heritability. European Group for the study of Insulin Resistance (EGIR).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

A comparison of the prevalence of the metabolic syndrome using two proposed definitions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Cardiometabolic syndrome and chronic kidney disease: what is the link?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Insulin resistance and its treatment by thiazolidinediones

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Type 2 diabetes, cardiovascular risk, and the link to insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Peroxisome proliferator-activated receptor gamma and metabolic disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Antihypertensive effects of CS-045 treatment in obese Zucker rats.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Anti-inflammatory effect of PPARgamma in cultured human mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Altered pressure-natriuresis in obese Zucker rats.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Rosiglitazone reduces urinary albumin excretion in type II diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Renal protective effect of troglitazone in Wistar fatty rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Peroxisome Proliferator-Activated Receptor γ Agonist Provides Superior Renal Protection versus Angiotensin-Converting Enzyme Inhibition in a Rat Model of Type 2 Diabetes with Obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Hepatic dysfunction associated with troglitazone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

The link between hyperglycaemia and diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

The effect of ruboxistaurin on nephropathy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Insulin, cation metabolism and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Translational regulation of renal proximal tubular epithelial cell transforming growth factor-beta1 generation by insulin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

ACE inhibitor-mediated attenuation of mesangial cell growth. A role for endothelin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Effect of insulin on systemic and renal handling of albumin in nondiabetic and NIDDM subjects.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Regression of albuminuria: latest evidence for a new approach

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Rosiglitazone Activates Renal Sodium- and Water-Reabsorptive Pathways and Lowers Blood Pressure in Normal Rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Clinical importance of microalbuminuria in diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Insulin, nitric oxide and the sympathetic nervous system: at the crossroads of metabolic and cardiovascular regulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Vascular function, insulin resistance and fatty acids

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Paradoxes of nitric oxide in the diabetic kidney

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Role of nitric oxide in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Troglitazone inhibits isolated cell proliferation, and induces apoptosis in isolated rat mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: thiazolidinediones are partial PPAR gamma agonists

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Pioglitazone attenuates TGF-beta(1)-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR)gamma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidinedione

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Inflammation and dyslipidemia in nephropathy: an epidemiologic perspective

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Agonist of peroxisome proliferator-activated receptor-gamma, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Role of oxidative stress in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Oxidative stress and glycemic regulation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Inhibition of oxidation of low density lipoprotein by troglitazone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Effect of pioglitazone on L-NAME induced hypertension in diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Troglitazone inhibits growth and improves insulin signaling by suppression of angiotensin II action in vascular smooth muscle cells from spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Inflammation modifies lipid-mediated renal injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Cellular lipid metabolism and the role of lipids in progressive renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Human mesangial cells express inducible macrophage scavenger receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Liver X receptor-alpha mediates cholesterol efflux in glomerular mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Dysregulation of LDL receptor under the influence of inflammatory cytokines: a new pathway for foam cell formation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Endogenous insulin modulates circulating endothelin-1 concentrations in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Renal actions of endothelin: linking cellular signaling pathways to kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

PPARgamma ligands attenuate mesangial contractile dysfunction in high glucose

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001620

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5001620

1 reference

14 August 2017

1 reference

PubMed ID

16883325